title: [Inhibitory effect of CMTM5 on xenografted human prostatic cancer in nude mice].
abstract: OBJECTIVE
  To investigate the inhibitory effect of CKLF-like MARVEL transmembrane domain containing 5 (CMTM5) on xenografted human prostatic cancer in nude mice and its action mechanism.
  
  
  METHODS
  We established a model of xenografted prostatic cancer by inoculating PC-3 cells subcutaneously into nude mice, and 3 weeks later injected CMTM5 adenovirus locally into the tumor followed by daily observation of the tumor volume and body weight of the experimental animals. All the rats were killed 2 weeks after CMTM5 injection and the tumor tissue harvested for detection of the inhibitory effect of CMTM5 on the expressions of VEGF and NF-kappaB proteins by immunohistochemistry.
  
  
  RESULTS
  The tumor volume was significantly smaller and body weight of the CMTM5-treated mice were (573.39 +/- 175.24) mm3 and (0.55 +/- 0.11) g, respectively, significantly decreased as compared with those of the controls ([1482.50 +/- 327.86] mm3 and [1.31 +/- 0.29] g) (P = 0.03 and P = 0.027). Immunohistochemistry showed that the expressions of VEGF and NF-kappaB were obviously down-regulated in the CMTM5 group in comparison with the control group.
  
  
  CONCLUSIONS
  CMTM5 suppresses the growth of prostate cancer by down-regulating the expressions of VEGF and NF-kappaB.
authors.affiliation: Department of Urology, People's Hospital of Peking University, Beijing 100044, China.
authors.forename: Yun-Bei
authors.initials: YB
authors.lastname: Xiao
authors.forename: Jing
authors.initials: J
authors.lastname: Xie
authors.forename: Gou-Xi
authors.initials: GX
authors.lastname: Zhang
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.forename: Yi-Chang
authors.initials: YC
authors.lastname: Hao
authors.forename: Xiao-Wei
authors.initials: XW
authors.lastname: Zhang
authors.forename: Zhen-Hua
authors.initials: ZH
authors.lastname: Liu
authors.forename: Tao
authors.initials: T
authors.lastname: Xu
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Wang
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D045744:Cell Line, Tumor; D018925:Chemokines / Q000235:genetics / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D062792:MARVEL Domain-Containing Proteins / Q000235:genetics / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D016328:NF-kappa B / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism*; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: C525020:CMTM5 protein, human; D018925:Chemokines; D062792:MARVEL Domain-Containing Proteins; D016328:NF-kappa B; D025521:Tumor Suppressor Proteins; D042461:Vascular Endothelial Growth Factor A